Trial Profile

A phase IIa study assessing Cannabidiol for COVID-19 infections

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections
Focus Proof of concept; Therapeutic Use

Most Recent Events

22 Apr 2020 New trial record
20 Apr 2020 According to a Stero Biotechs media release, the company plans to scale up and expand to a phase 2a multi-center clinical trial, with an additional 40 hospitalized patients with COVID-19 Infections, under FDA clinical trial guidelines and regulations.
20 Apr 2020 According to a Stero Biotechs media release, this study will commence in Rabin Medical Center Golda HaSharon Campus in Israel. This study will begin in April ,pending final Helsinki Committee approval.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com